Tracy Staton

Biography for Tracy Staton

Tracy Staton, Senior Editor

Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at tracy@fiercemarkets.com or find her on LinkedIn.

Articles by Tracy Staton

Slimdown craze still on, with sales and spinoffs galore. Slim fast? Not necessarily

Restructuring is an all-purpose word. It can be a euphemism for layoffs. It can mean a quick redraw of the corporate organizational chart. It can cover big shifts in management responsibilities and operations. It can handle even bigger moves, like AstraZeneca's headquarters shift, R&D overhaul, and worldwide job cuts. And then there's restructuring with a capital R.

Justice Department sues Omnicare for rigging kickbacks with Abbott

Once again, long-term care pharmacy Omnicare is at the center of a Department of Justice kickback probe. This time, the drugmaker in focus is Abbott Laboratories. The drug, Depakote.

AstraZeneca CEO says Pfizer won't come back. Oh, and that $45B goal? It's a stretch

In one interview published over the weekend, AstraZeneca CEO Pascal Soriot pooh-poohed the idea of Pfizer coming back with another takeover bid. In another, he gave a subtle warning about his company's stated goal of hitting $45 billion in sales within a decade.

Sorry, Gilead. AbbVie cuts exclusive hep C deal with Express Scripts

AbbVie has made Express Scripts' wish come true. Or perhaps it's the other way around. The proud new parent of Viekira, a highly anticipated hepatitis C cocktail, AbbVie now has exclusive access to millions of the pharmacy benefits manager's patients in return for a "significant discount" off its $85,000 list price.

Wishing, hoping, planning as AbbVie's hep C do-or-die moment nears

As 2014 winds down, and Gilead Sciences keeps winding up hep C sales by the billion, AbbVie waits, vibrating with anticipation. Its three-drug cocktail is up for FDA approval any day now, and the Illinois-based company is ready to challenge Gilead for market share.

Court's decision on Namenda 'hard switch' could spill over into precedent

Last week, a New York judge called a halt on Actavis' plan to pull Namenda off the market, throwing off its strategy for switching patients to a newer extended-release version.

Pfizer, Bayer and Boehringer meds win backing from U.K. cost agency

This week, the U.K. National Institute for Health and Care Excellence blessed Pfizer's kidney cancer treatment Inlyta, changed its mind in support of Bayer's prostate cancer therapy Xofigo, and backed Boehringer Ingelheim's anticoagulant Pradaxa for blood clots in the legs and lungs.

Gilead chief racks up best-CEO laurels for Sovaldi-fueled 2014

After winning top reviews from the Harvard Business Review for his 2014 performance, Gilead Sciences CEO John Martin has picked up a "best CEO" nod from a Tuck School of Business prof. And the investing site Motley Fool puts him among the year's three "most exceptional" corporate chiefs.

Roche's Lucentis nabs FDA 'breakthrough' tag for diabetic eye disease

Roche's Lucentis may now have a bigger jump on Eylea in diabetic retinopathy. The Swiss drugmaker's Genentech unit won the FDA's "breakthrough" designation for that indication on Monday. And Lucentis was already on the FDA's priority review track, with a decision date in February.

Fresh off Afinitor failure, Novartis turns tide with Signifor LAR approval

It's been a good news, bad news week for Novartis and its oncology business. Monday, the Swiss drugmaker won FDA approval for a long-acting version of Signifor, to treat acromegaly, a rare endocrine disorder. But Friday, Novartis announced that Afinitor fell short in a HER2-positive breast cancer trial, dashing hopes for what could have been a lucrative new indication.